{"anticipatedPostingDate":"2010-05","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Detection of an absolute donor derived cell count of \\> or = 100 cells/mL after NK cell infusion.","groups":[{"description":"This group includes patients with recurrent ovarian, fallopian tube or primary peritoneal cancer who received at least one dose of chemotherapy (cyclophosphamide 60 mg/m\\^2 and fludarabine 25 mg/m\\^2 for 2 doses, and aldesleukin 10 million units for 6 doses), infusion of natural killer cells (1.5-8.0 \\* 10\\^7 kg) and/or total body irradiation per protocol (200 Gy on Day 1 preceding natural killer cell infusion).","id":"OG000","title":"Ovarian/Fallopian Tube/Peritoneal Cancer Patients"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day 12-14","title":"Number of Patients With In Vivo Expansion of Infused Allogeneic Natural Killer (NK) Cell Product","type":"PRIMARY","unitOfMeasure":"Patients"}